GlassScriptPhysician profile
Atif A Qureshi
NPI 1629014790
$6,338.94
in general payments reported to CMS, 2019-2025
35 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $623 · 2021: $1,214 · 2022: $885 · 2023: $809 · 2024: $968 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,873 · Education: $86.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,872.88 |
| Education | $86.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,185.66 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $520.16 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $487.37 | 2020-2024 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals LP | $483.59 | 2019-2024 | Farxiga |
| Opko Pharmaceuticals, LLC | $429.80 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $392.41 | 2020-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $348.83 | 2022-2025 | |
| Travere Therapeutics, INC. | $263.91 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $220.93 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $205.57 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $161.37 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $154.57 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $152.92 | 2019-2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $149.52 | 2022-2024 | Gattex |
| Fresenius USA Marketing, INC. | $135.62 | 2019-2024 | Velphoro |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atif Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.